knowledge -WSS

knowledge

author：entertainment 2025-09-30 01:01:22 - browse：39

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： First U.S. drug developed to treat liver disease MASH is approved

WSS

Medicare coverage of Wegovy, once blocked, now looks possible

Why do we get seasonal allergies?

Medical experts exlpore how to eliminate bias in clinical algorithms

Readout Newsletter: CAR

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

WuXi out of biotech trade group, U.S. and China relations to blame

focus

knowledge

focus

Sports medicine is finally prioritizing gender equality

Male and female sex labels in research insufficient, scientists say

Activists slam private health insurers over coverage restrictions

The simple reason for the increase in autism diagnosis

Peter Hotez and the public health issue of online harassment

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

In Memoriam: Notable people who died in 2023

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Walensky prepares to leave CDC — and Congress — behind

GOP inquiry over gain

hotspot

Synthetic human embryos? Researchers say term is overblown

Tuskegee Airman Raymond Cassagnol dies at 102

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

The simple reason for the increase in autism diagnosis

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

hotspot

entertainment

explore

focus